Stanford University cancer screening spinout CAPP Medical has been acquired by Roche.
CAPP Medical, a genomics research spinout from Stanford University, has been acquired by Switzerland-based healthcare research company Roche.
Details of the acquisition have not been disclosed.
The acquisition will allow CAPP Medical to continue working on the development of its technology that screens for cancer and monitors its progress through the detection of tumour DNA circulating in a patient’s blood.
Ashok Krishnamurthi, chief executive of CAPP Medical, said: “This acquisition highlights Roche’s commitment to advancing cancer testing. We strongly believe Roche is the best suited company to advance this technology and bring it to its full potential.”
CAPP Medical was founded in October 2013.
Roland Diggelmann chief operating officer for Roche Diagnostics, said: “Roche believes focused and high quality next generation sequencing assays using simple blood draws have the potential to significantly advance the time of cancer diagnosis and change routine cancer diagnostic monitoring and may be highly cost effective compared to today’s current standard of using PET and CT imaging to monitor tumour progression.”
